VYNE Therapeutics Inc. recently announced positive results from the Phase 1a portion of its Phase 1a/b clinical trial evaluating its novel BET inhibitor, VYN201, for vitiligo.

This drug candidate is a locally administered, small molecule, pan-bromodomain and extra-terminal domain (BET) inhibitor. VYN201 was found to upregulate the WNT signaling pathway which is an important mediator of both melanogenesis and melanocyte differentiation and is known to be dysregulated in patients with vitiligo. Library of BET inhibitors is licensed from Tay Therapeutics Ltd,  and protected by a GB patent titled 'Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts.'

30 healthy volunteers were given single and multiple ascending doses of VYN201 ointment in five dose cohorts over two weeks, with a one-week safety follow-up visit. The doses included 0.025%, 0.1%, 0.5%, 1.0% and 2.0%, and it was generally well-tolerated with no clinically relevant adverse events from all dose cohorts.

In addition to the safety assessment, exploratory efficacy of VYN201 in non-segmental vitiligo patients will be evaluated, including pharmacodynamic biomarkers and photography.

These positive results have also caused VYNE Therapeutics shares to increase 8%.

📌 Vitiligo Drug Pipeline Analysis and Market Insights